![]() These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. In addition, the company may discuss certain non-GAAP financial measures during today’s call. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. Important factors which could cause actual results to differ materially from those in these forward-looking statements are detailed in Co-Diagnostics filings with the SEC. However, these statements are not guarantees of performance and involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results expressed or implied by such statements. This company begins - the company believes these statements are based on reasonable assumptions. This includes statements concerning the company’s forthcoming Co-Dx PCR Home testing platform, which is subject to FDA review and is not yet available for sale. For example, statements concerning 2023 financial and operational guidance, the development, regulatory clearance, commercialization and features of new products, plans and objectives of management and market trends are all forward-looking statements. Any statement about company expectations, beliefs, plans, objectives, assumptions of future events or performance are forward-looking statements. We will begin the call with management’s prepared remarks and then open up the call to questions from our analysts.īefore we begin, we would like to inform the listeners that certain statements made by Co-Diagnostics during the course of this call may constitute forward-looking statements. I’m Andrew Benson, and joining me this afternoon are members of the Co-Diagnostics management team, including Dwight Egan, Chief Executive Officer and Brian Brown, Chief Financial Officer. ![]() I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. Please note that this event is being recorded today. After today’s presentation, there will be an opportunity to ask questions. All participants will be in a listen-only mode. Fourth Quarter and Full Year 2022 Earnings Results Conference Call. ![]() Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Operator: Good afternoon, and welcome to the Co-Diagnostics, Inc. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.įintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). (This description is provided by the company.)Ĭo-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The firm decreased its portfolio allocation in CODX by 5.66% over the last quarter.īridgeway Capital Management holds 273K shares representing 0.89% ownership of the company. In it's prior filing, the firm reported owning 302K shares, representing a decrease of 2.63%. Geode Capital Management holds 294K shares representing 0.96% ownership of the company. VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 445K shares representing 1.45% ownership of the company. The firm increased its portfolio allocation in CODX by 9.99% over the last quarter. In it's prior filing, the firm reported owning 654K shares, representing a decrease of 2.72%. Renaissance Technologies holds 636K shares representing 2.08% ownership of the company. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,279K shares representing 4.18% ownership of the company. The put/call ratio of CODX is 0.19, indicating a bullish outlook. Total shares owned by institutions decreased in the last three months by 11.05% to 4,780K shares. ![]() Average portfolio weight of all funds dedicated to CODX is 0.01%, a decrease of 38.65%. This is a decrease of 14 owner(s) or 16.28% in the last quarter. There are 72 funds or institutions reporting positions in Co-Diagnostics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |